Galdames D G, Saavedra I N, Ortiz M A, Aguilera L I, Valenzuela A L, Concha G L, Droguett P A, Morales E R
Epilepsia. 1980 Oct;21(5):467-74. doi: 10.1111/j.1528-1157.1980.tb04297.x.
In a prospective study of 117 adult ambulatory patients, 110 of whom were epileptics treated only with oral diphenylhydantoin (DPH), plasma levels of this drug were determined by gas-liquid chromatography. The average follow-up time was 6 months (range, 3 to 13 months); satisfactory control of seizures was obtained with plasma levels in the 10.2 to 25.8 micrograms/ml range, representing 68% of the patients whose seizures had been controlled. The dosage received by this group was from 4.2 to 6 mg/kg, with an average of 5.1. In general, these results agree with those found in European or North American patients, even though some differences or little clarity in the methodology of other trials make comparison difficult. This similarity of results makes one think that genetic or environmental differences do not alter the response to DPH in our patients, but further studies are necessary in that area. This paper can serve as a basis for the extrapolation of data about DPH coming from other latitudes that have been considered supposedly valid for Latin American epileptic patients.
在一项针对117名成年门诊患者的前瞻性研究中，其中110名是仅接受口服苯妥英（DPH）治疗的癫痫患者，通过气液色谱法测定了该药物的血浆水平。平均随访时间为6个月（范围为3至13个月）；癫痫发作得到满意控制的患者，其血浆水平在10.2至25.8微克/毫升范围内，占癫痫发作得到控制患者的68%。该组患者的剂量为4.2至6毫克/千克，平均为5.1毫克/千克。总体而言，这些结果与在欧洲或北美患者中发现的结果一致，尽管其他试验方法存在一些差异或不够清晰，使得比较困难。结果的相似性使人认为，遗传或环境差异并未改变我们患者对DPH的反应，但该领域仍需进一步研究。本文可作为推断来自其他地区有关DPH数据的基础，这些数据被认为对拉丁美洲癫痫患者可能有效。
